ATE375153T1 - Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension - Google Patents
Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertensionInfo
- Publication number
- ATE375153T1 ATE375153T1 AT00911767T AT00911767T ATE375153T1 AT E375153 T1 ATE375153 T1 AT E375153T1 AT 00911767 T AT00911767 T AT 00911767T AT 00911767 T AT00911767 T AT 00911767T AT E375153 T1 ATE375153 T1 AT E375153T1
- Authority
- AT
- Austria
- Prior art keywords
- sulfur
- oxygen
- hydrogen
- nitrogen
- epoxydhydrolase
- Prior art date
Links
- 206010020772 Hypertension Diseases 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 229910052757 nitrogen Inorganic materials 0.000 abstract 3
- 229910052760 oxygen Inorganic materials 0.000 abstract 3
- 239000001301 oxygen Substances 0.000 abstract 3
- 229910052717 sulfur Inorganic materials 0.000 abstract 3
- 239000011593 sulfur Substances 0.000 abstract 3
- 102000005486 Epoxide hydrolase Human genes 0.000 abstract 2
- 108020002908 Epoxide hydrolase Proteins 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 239000003112 inhibitor Substances 0.000 abstract 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 102100025357 Lipid-phosphate phosphatase Human genes 0.000 abstract 1
- 108030006933 Soluble epoxide hydrolases Proteins 0.000 abstract 1
- 125000002252 acyl group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- -1 cycloakyl Chemical group 0.000 abstract 1
- 239000007857 degradation product Substances 0.000 abstract 1
- 125000001188 haloalkyl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 239000002207 metabolite Substances 0.000 abstract 1
- 238000000926 separation method Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/252,148 US6150415A (en) | 1996-08-13 | 1999-02-18 | Epoxide hydrolase complexes and methods therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE375153T1 true ATE375153T1 (de) | 2007-10-15 |
Family
ID=22954799
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00911767T ATE375153T1 (de) | 1999-02-18 | 2000-02-10 | Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US6150415A (de) |
| EP (2) | EP1154764B1 (de) |
| JP (1) | JP2002540767A (de) |
| AT (1) | ATE375153T1 (de) |
| AU (1) | AU3360800A (de) |
| CA (1) | CA2362331C (de) |
| DE (1) | DE60036690T2 (de) |
| DK (1) | DK1154764T3 (de) |
| ES (1) | ES2291196T3 (de) |
| WO (1) | WO2000048593A1 (de) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US8815951B2 (en) * | 1996-08-13 | 2014-08-26 | The Regents Of The University Of California | Inhibitors of epoxide hydrolases for the treatment of inflammation |
| US7517880B2 (en) | 1997-12-22 | 2009-04-14 | Bayer Pharmaceuticals Corporation | Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas |
| US7928239B2 (en) | 1999-01-13 | 2011-04-19 | Bayer Healthcare Llc | Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US7351834B1 (en) | 1999-01-13 | 2008-04-01 | Bayer Pharmaceuticals Corporation | ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| ATE556713T1 (de) * | 1999-01-13 | 2012-05-15 | Bayer Healthcare Llc | Omega-carboxyarylsubstituierte-diphenyl- harnstoffe als p38-kinasehemmer |
| US8124630B2 (en) | 1999-01-13 | 2012-02-28 | Bayer Healthcare Llc | ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| EP1140840B1 (de) * | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren |
| US6831099B1 (en) * | 1999-05-12 | 2004-12-14 | Yale University | Enzyme inhibition |
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| US6562563B1 (en) * | 1999-11-03 | 2003-05-13 | Mitokor | Compositions and mehtods for determining interactions of mitochondrial components, and for identifying agents that alter such interactions |
| US7235576B1 (en) | 2001-01-12 | 2007-06-26 | Bayer Pharmaceuticals Corporation | Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
| WO2002082082A2 (en) * | 2001-04-09 | 2002-10-17 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorescence polarization assay |
| US7371763B2 (en) | 2001-04-20 | 2008-05-13 | Bayer Pharmaceuticals Corporation | Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas |
| US6756210B2 (en) * | 2001-05-29 | 2004-06-29 | The Regents Of The University Of California | Linoleic acid diol and glucuronide conjugate levels as diagnostic markers of disorders of abnormal regulation of cytochrome P450 metabolism of unsaturated fatty acids |
| US6943001B2 (en) * | 2001-08-03 | 2005-09-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| CA2456229A1 (en) * | 2001-08-03 | 2003-02-13 | Diversa Corporation | Epoxide hydrolases, nucleic acids encoding them and methods for making and using them |
| US20030139469A1 (en) * | 2002-01-23 | 2003-07-24 | The Regents Of The University Of California | Use of inhibitors of soluble epoxide hydrolase to inhibit vascular smooth muscle cell proliferation |
| AU2003209116A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
| AU2003209119A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Pharmaceuticals Corporation | Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors |
| EP1474393A1 (de) | 2002-02-11 | 2004-11-10 | Bayer Pharmaceuticals Corporation | Aryl-harnstoffe als kinase inhibitoren |
| GB0214342D0 (en) * | 2002-06-21 | 2002-07-31 | Givaudan Sa | Insect repellents |
| AU2003279877B2 (en) | 2002-10-07 | 2010-05-20 | The Regents Of The University Of California | Modulation of anxiety through blockade of anandamide hydrolysis |
| US7557129B2 (en) | 2003-02-28 | 2009-07-07 | Bayer Healthcare Llc | Cyanopyridine derivatives useful in the treatment of cancer and other disorders |
| US20050026844A1 (en) | 2003-04-03 | 2005-02-03 | Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| US20050164951A1 (en) * | 2003-04-03 | 2005-07-28 | The Regents Of The University Of California | Inhibitors for the soluble epoxide hydrolase |
| PT1636585E (pt) | 2003-05-20 | 2008-03-27 | Bayer Pharmaceuticals Corp | Diarilureias com actividade inibidora de cinase |
| NZ544920A (en) | 2003-07-23 | 2009-11-27 | Bayer Healthcare Llc | 4{4-[3-(4-chloro-3-trifluoromethylphenyl)-ureido]-3-fluorophenoxy}-pyridine-2-carboxylic acid methylamide and metabolites for the treatment and prevention of diseases and conditions |
| EP1765311A4 (de) * | 2004-03-16 | 2009-04-29 | Univ California | Verringerung von nephropathie mit hemmern der löslichen epoxid-hydrolase und von epoxyeicosanoiden |
| ES2257152B1 (es) * | 2004-05-31 | 2007-07-01 | Laboratorios Almirall S.A. | Combinaciones que comprenden agentes antimuscarinicos y agonistas beta-adrenergicos. |
| CA2584342C (en) * | 2004-10-20 | 2013-04-30 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| EP1885361A2 (de) * | 2005-05-06 | 2008-02-13 | Boehringer Ingelheim International GmbH | Acylhydrazone zur behandlung von herz-kreislauf-erkrankungen |
| JP2008540433A (ja) * | 2005-05-06 | 2008-11-20 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 可溶性エポキシドヒドロラーゼインヒビター及びその使用方法 |
| US9119837B2 (en) * | 2005-08-19 | 2015-09-01 | The Regents Of The University Of California | Use of sEH inhibitors as analgesics |
| CA2622754A1 (en) * | 2005-10-07 | 2007-04-19 | Boehringer Ingelheim International Gmbh | N-substituted pyridinone or pyrimidinone compounds useful as soluble epoxide hydrolase inhibitors |
| KR101434522B1 (ko) | 2005-11-09 | 2014-08-26 | 오닉스 세라퓨틱스, 인크. | 효소 저해를 위한 화합물 |
| US8791163B2 (en) * | 2006-01-13 | 2014-07-29 | Mcgill University | Melatonin ligands having antidepressant activity as well as sleep inducing properties |
| CA2643859A1 (en) * | 2006-03-10 | 2007-09-20 | Boehringer Ingelheim International Gmbh | Soluble epoxide hydrolase inhibitors and methods of using same |
| AR059826A1 (es) | 2006-03-13 | 2008-04-30 | Univ California | Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble |
| US7691852B2 (en) | 2006-06-19 | 2010-04-06 | Onyx Therapeutics, Inc. | Compounds for enzyme inhibition |
| US8263651B2 (en) * | 2006-12-15 | 2012-09-11 | The Regents Of The University Of California | Use of cis-epoxyeicosatrienoic acids and inhibitors of soluble epoxide hydrolase to treat conditions mediated by PBR, CB2, and NK2 receptors |
| CN101563088A (zh) * | 2006-12-18 | 2009-10-21 | 弗·哈夫曼-拉罗切有限公司 | 可溶性环氧化物水解酶的抑制剂的新用途 |
| US8455520B2 (en) * | 2007-07-17 | 2013-06-04 | Merck Sharp & Dohme Corp. | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| EP2187746A4 (de) * | 2007-08-06 | 2011-01-19 | Univ California | Herstellung von neuen 1,3-substituierten harnstoffen als hemmer der löslichen epoxidhydrolase |
| RS54847B2 (sr) | 2007-10-04 | 2019-09-30 | Onyx Therapeutics Inc | Inhibitori kristalne peptid epoksi keton proteaze i sinteza aminokiselinskih keto-epoksida |
| US20110003849A1 (en) * | 2008-03-04 | 2011-01-06 | Hong Shen | Soluble epoxide hydrolase inhibitors, compositions containing such compounds and methods of treatment |
| EP2100599A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
| EP2100598A1 (de) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalationszusammensetzung enthaltend Aclidinium zur Behandlung von Asthma sowie chronisch-obstruktiver Lungenerkrankung |
| JP5675629B2 (ja) | 2008-10-21 | 2015-02-25 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | ペプチドエポキシケトンを用いた併用療法 |
| WO2010096722A1 (en) | 2009-02-20 | 2010-08-26 | Takeda Pharmaceutical Company Limited | 3-oxo-2, 3-dihydro- [1,2, 4] triazolo [4, 3-a]pyridines as soluble epoxide hydrolase (seh) inhibitors |
| AR075899A1 (es) | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
| JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． | 転移抑制のためのペプチドエポキシケトンの使用 |
| EP2528604B1 (de) | 2010-01-29 | 2017-11-22 | The Regents of the University of California | Acylpiperidinhemmer aus löslicher epoxidhydrolase |
| MA34133B1 (fr) | 2010-03-01 | 2013-04-03 | Onyx Therapeutics Inc | Composes pour inhibiteurs de l'immunoproteasome |
| WO2011136905A2 (en) | 2010-04-07 | 2011-11-03 | Onyx Therapeutics, Inc. | Crystalline peptide epoxyketone immunoproteasome inhibitor |
| EP2389922A1 (de) | 2010-05-25 | 2011-11-30 | Symrise AG | Cyclohexylcarbamatverbindungen als Anti-ageing-Wirkstoffe |
| CA2826277A1 (en) | 2011-02-14 | 2012-08-23 | The Regents Of The University Of California | Sorafenib derivatives as seh inhibitors |
| EP2510928A1 (de) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium zur Verbesserung der Schlafqualität bei atemwegserkrankten Patienten |
| EP2809650B1 (de) | 2012-02-01 | 2018-04-11 | The Regents of The University of California | Acylpiperidinderivate als inhibitoren der löslichen epoxidhydrolase |
| WO2013138118A1 (en) | 2012-03-14 | 2013-09-19 | The Regents Of The University Of California | Treatment of inflammatory disorders in non-human mammals |
| US20140105921A1 (en) | 2012-07-09 | 2014-04-17 | Onyx Therapeutics, Inc. | Prodrugs of Peptide Epoxy Ketone Protease Inhibitors |
| WO2016133788A1 (en) | 2015-02-20 | 2016-08-25 | The Regents Of The University Of California | Methods of inhibiting pain |
| US20200317813A1 (en) | 2016-05-25 | 2020-10-08 | Johann Wolfgang Goethe-Universitat Frankfurt Am Main | Treatment and diagnosis of non-proliferative diabetic retinopathy |
| WO2020074549A1 (en) | 2018-10-10 | 2020-04-16 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and topical pharmaceutical compositions for the treatment of skin microvascular dysfunction |
| JP7498708B2 (ja) | 2018-11-09 | 2024-06-12 | ギンゴー バイオワークス， インコーポレイテッド | モグロシドの生合成 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1056290A (en) * | 1963-05-06 | 1967-01-25 | Du Pont | Dicycloalkyl ureas |
| CA2017383A1 (en) * | 1989-06-08 | 1990-12-08 | Raymond R. Martodam | Use of vanilloids for the treatment of respiratory diseases or disorders |
| AU636713B2 (en) * | 1990-02-26 | 1993-05-06 | Merrell Dow Pharmaceuticals Inc. | Inhibitors of nitric oxide biosynthesis |
| US5445956A (en) * | 1993-08-13 | 1995-08-29 | The Regents Of The University Of California | Recombinant soluble epoxide hydrolase |
| US5599984A (en) * | 1994-01-21 | 1997-02-04 | The Picower Institute For Medical Research | Guanylhydrazones and their use to treat inflammatory conditions |
| JP2909620B2 (ja) * | 1995-03-07 | 1999-06-23 | 参天製薬株式会社 | Ｎ，ｎ−ジアルキルアミノフェニル基を有する新規アミノ酸誘導体 |
| US6150415A (en) * | 1996-08-13 | 2000-11-21 | The Regents Of The University Of California | Epoxide hydrolase complexes and methods therewith |
| US5955496A (en) * | 1996-08-13 | 1999-09-21 | The Regents Of The University Of California | Dihydroxy-oxy-eicosadienoates |
-
1999
- 1999-02-18 US US09/252,148 patent/US6150415A/en not_active Expired - Lifetime
-
2000
- 2000-02-10 AU AU33608/00A patent/AU3360800A/en not_active Abandoned
- 2000-02-10 JP JP2000599385A patent/JP2002540767A/ja active Pending
- 2000-02-10 EP EP00911767A patent/EP1154764B1/de not_active Expired - Lifetime
- 2000-02-10 ES ES00911767T patent/ES2291196T3/es not_active Expired - Lifetime
- 2000-02-10 DE DE60036690T patent/DE60036690T2/de not_active Expired - Lifetime
- 2000-02-10 AT AT00911767T patent/ATE375153T1/de active
- 2000-02-10 CA CA2362331A patent/CA2362331C/en not_active Expired - Fee Related
- 2000-02-10 EP EP07014966A patent/EP1844767B1/de not_active Expired - Lifetime
- 2000-02-10 WO PCT/US2000/003495 patent/WO2000048593A1/en not_active Ceased
- 2000-02-10 DK DK00911767T patent/DK1154764T3/da active
Also Published As
| Publication number | Publication date |
|---|---|
| US6150415A (en) | 2000-11-21 |
| AU3360800A (en) | 2000-09-04 |
| EP1844767A2 (de) | 2007-10-17 |
| EP1154764B1 (de) | 2007-10-10 |
| EP1844767B1 (de) | 2012-08-29 |
| CA2362331A1 (en) | 2000-08-24 |
| CA2362331C (en) | 2010-04-20 |
| JP2002540767A (ja) | 2002-12-03 |
| DE60036690D1 (de) | 2007-11-22 |
| WO2000048593A1 (en) | 2000-08-24 |
| DK1154764T3 (da) | 2008-02-04 |
| EP1844767A3 (de) | 2010-01-13 |
| ES2291196T3 (es) | 2008-03-01 |
| DE60036690T2 (de) | 2008-07-17 |
| EP1154764A4 (de) | 2005-02-16 |
| EP1154764A1 (de) | 2001-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE375153T1 (de) | Verwendung von epoxydhydrolasekomplexe zur behandlung von hypertension | |
| NZ505968A (en) | Sulfonylamino derivatives which inhibit matrix- degrading metallproteinases | |
| ATE202702T1 (de) | Verwendung von oestrogenagonisten und - antagonisten zur herstellung eines medikaments zur behandlung von atherosklerose, unabhängig von lipidsenkung | |
| TR200402157T2 (tr) | Heteroaril süksinamidler ve metalloproteinaz inhibitörü olarak kullanımları | |
| ES2196396T3 (es) | Compuestos heteroaromaticos de 5 miembros conteniendo oxigeno o azufre como inhibidores del factor xa. | |
| RU95105988A (ru) | Производные эфиров о-бензилоксимов, способ их получения и пестицидная композиция на их основе | |
| EA200500875A1 (ru) | Производные 3-аминопирролидина в качестве модуляторов рецепторов хемокинов | |
| DE69332792D1 (de) | 4,1-Benzoxazepinderivate als Squalen-Synthetase Inhibitoren und ihre Verwendung zur Behandlung von Hypercholesterämie und als Fungizide | |
| ES2054899T3 (es) | Derivados de 2'-desoxi-5-fluorouridina. | |
| ES2164164T3 (es) | Derivados de aminotetrazol utiles como inhibidores de oxido nitrico sintasa. | |
| BR9508901A (pt) | Di-hidrobenzofurano e composto relacionados utilizáveis como agentes antiflamatórios | |
| PH19684A (en) | Biologically acitve heterocyclic compounds | |
| DE69319764D1 (de) | Verfahren zur Herstellung von Beta-Lactamderivaten und Zwischenprodukt für ihre Synthese | |
| ATE224372T1 (de) | Substituierte 6-alkylphenanthridine | |
| PL336857A1 (en) | Heterocyclic compounds, method of obtaining them and pharmaceutic composition containing such compounds | |
| ATE247660T1 (de) | Furopyridinderivate und ihre therapeutische verwendung | |
| BR9813923A (pt) | N n - bis(sulfonil) hidrazinas úteis como agentes antineoplásicos | |
| MY121785A (en) | Hydroxamic acid derivatives as inhibitors of the production of soluble cd23 | |
| BR9707321A (pt) | Dihidrobenzofurano e compostor correlatos úteis como agentes antinflamatórios | |
| ATE170516T1 (de) | Alkylendiaminderivate | |
| ATE255561T1 (de) | Verfahren und zusammensetzungen zur behandlung von leukämie | |
| ATE120741T1 (de) | N-hydroxy-dibenz(b,e>oxepin-alkylamine und - alkanoische säureamide, verwandte heterocyclische analoge, verfahren zu ihrer herstellung und ihre verwendung zur herstellung von medikamenten. | |
| ATE253050T1 (de) | Aminderivate von oxo- und hydroxy- substituierten kohlenwasserstoffen | |
| BR0110328A (pt) | Compostos heterocìclicos com atividade antiinflamatória | |
| YU47797B (sr) | Heterociklična jedinjenja koja sadrže azot i sumpor i postupci za njihovo dobijanje |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1154764 Country of ref document: EP |